PV Bulletin

Withdrawal of FastPen 40mg Product by AZRL LTD

The ANSM decreed the withdrawal of the FastPen 40mg product, identified as containing a GLP-1 agonist, due to safety concerns.

Primary source: PUBLIÉ LE 19/11/2025 - MIS À JOUR LE 31/08/2026 L’ANSM prend des mesures de police sanitaire à l’encontre des sites inte

Translated From French

PV Bulletin does not take any responsibility for translation errors or omissions, though it has used the best available translation engine.

PV Impact Brief

Urgency: HighConfidence: high

What changed

The product 'FastPen 40mg' has been officially withdrawn from the market, necessitating an immediate recall by AZRL LTD.

Why it matters

This regulatory action highlights serious safety concerns regarding the medication, mandating compliance to protect public health.

Action needed

AZRL LTD must proceed with the recall of FastPen 40mg from all locations and suspend marketing activities until compliance is verified.

Relevant for
Regulatory Intelligence LeadMedical Safety Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Aug 31, 2026

Full briefing

Practical implication

AZRL LTD must proceed with the recall of FastPen 40mg from all locations and suspend marketing activities until compliance is verified.

The French National Agency for the Safety of Medicines and Health Products (ANSM) announced on August 14, 2026, the withdrawal of FastPen 40mg by AZRL LTD, due to safety issues associated with its use as a GLP-1 agonist. The decision includes an immediate recall of the product and a suspension of its marketing until compliance with regulations is achieved.

What changed: The product 'FastPen 40mg' has been officially withdrawn from the market, necessitating an immediate recall by AZRL LTD.

Why it matters: This regulatory action highlights serious safety concerns regarding the medication, mandating compliance to protect public health.

Practical implication: AZRL LTD must proceed with the recall of FastPen 40mg from all locations and suspend marketing activities until compliance is verified.

View original source

  • Source: ANSM (France) - News feed
  • Published at source: 2026-08-31T00:00:00.000Z
  • Discovered by monitor: 2026-08-31T21:32:58.820Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signal#Safety Signals#Source-ingestion#Regulator-monitor#Translated From French#France#Ansm.sante.fr

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward